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1. Introduction 
The antitumour activity of crude preparations of 
bulbs from species of Narcissus [l] is due to the 
alkaloid narciclasine, of known chemical structure 
[2,3], which exerts an antimitotic effect during 
metaphase [4]. Studies in our laboratory have shown 
that narciclasine immediately halts protein synthesis 
in Ehrlich ascites tumour and Saccharomyces 
cerevisiae cells without affecting RNA synthesis 
(A. Jimenez, personal communication). The results 
presented in this communication show that narcic- 
lasine inhibits protein synthesis in rabbit reticulocyte 
and yeast cell-free systems by blocking peptide bond 
formation at the ribosome level. 
2. Materials and methods 
Reticulocyte ribosomes and elongation factors 
EF 1 and EF 2 were prepared from anaemic rabbits 
as previously described [5-71. Yeast polysomes and 
a crude supernatant fraction containing the elongation 
factors were prepared as described [8]. 
Poly U-directed [ r4 C] phenylalanine incorporation 
using either rabbit reticulocyte or E. coli ribosomes 
was assayed following standard methods described 
elsewhere [7,9]. Polypeptide synthesis by yeast 
cell-free systems was studied in 50 fl reaction mixtures 
containing 50 mM Tris-HCl buffer, pH 7.4, 12 mM 
MgClz , 50 mM KCl, 1 mM dithiothreitol, 1 mM ATP, 
80 pg GTP, 4 mM creatine phosphate, 40 pg/ml 
creatine phosphokinase, 40 /,&ml yeast tRNA, 15 Erg 
of 19 non-radioactive aminoacids (phenylalanine was 
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omitted), 0.015 mM [’ 4C] phenylalanine (190 mCi/ 
mmol), 5 ~1 of a crude supernatant fraction and 28 
pmol yeast polysomes. Polypeptide synthesis was 
stopped by the addition of 2 ml of 10% trichloro- 
acetic acid. After heating for 10 min at 90°C the 
mixtures were filtered through GF/C glass fibre 
Whatman filters, the filters were dried, and radio- 
activity estimated in a scintillation spectrometer. 
Peptide bond formation was studied by estimation 
of the release of nascent peptides on yeast polysomes 
by [3 Hlpuromycin and the puromycin reaction with 
either Ac-[~H]P~~-~RNA or UACCA-[3H] Leu-AC 
bound to rabbit reticulocyte ribosomes. The release 
of nascent peptides was studied in 50 fi reaction 
mixtures of 50 mM Tris-HCl buffer, pH 7.4, 12.5 
mM MgCl,, 80 mM KCl, 0.5 mM GTP, 7 1.11 of a crude 
supernatant fraction and 43 pmol yeast polysomes 
incubated for 10 min at 30°C to allow translocation 
of the peptidyl-tRNA from the A ribosomal site to the 
P-site; The required concentration of narciclasine and 
2 pmol [ 3 H] puromycin (3.7 Ci/mmol) were then 
added, the incubation continued for 1 min at 30°C 
the reaction stopped by addition of 2 ml 10% trichloro- 
acetic acid and the radioactivity retained on glass 
fibre filters estimated. The reaction of the complex 
AC-[j HIPhe-tRNA (7.8 Ci/mmol)-rabbit reticulocyte 
ribosome-poly U with puromycin was carried out as 
described [9, lo] . The reaction of puromycin UACCA- 
[3 H] Leu-AC (52 Ci/mmol) bound to rabbit reticu- 
locyte ribosomes (the ‘fragment reaction’ assay) was 
performed as previously described [ 1 I] . 
Non-enzymic binding of AC- [3 H] Phe-tRNA 
(7.8 Ci/mmol), enzymic binding of [ l4 C] Phe-tRNA 
(476 mCi/mmol) and sparsomycin-induced binding of 
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UACCA-[3 H] Leu-AC 52 Ci/mmol to rabbit reticu- 
locyte ribosomes was carried out as previously 
described [I 1,121. 
Binding of [3 H] anisomycin and [ l4 C] trichodermin 
to ribosomes was carried out in 60 /.11 mixtures which 
contained 50 mM Tri-HCl buffer, pH 7.4, 12.5 mM 
magnesium chloride, 80 mM KCl, either 11.5 mg/ml 
yeast ribosomes of 9 mg/ml rabbit reticulocyte 
ribosomes and either 1 0T6 M [ 14C] trichodermin 
(15.4 mCi/mmol). The ultracentrifugation method 
described previously [ 131 was used. 
[ 3 H] anisomycin and [’ 4 C] trichodermin were 
prepared by Dr M. Barbacid following methods 
described elsewhere [ 13,141. Narciclasine was 
prepared [2] and given to us by Dr Piozzi. Sparsomycin 
and trichodermin were supplied to us as described 
elsewhere [ 10,121. [14C]Phe-tRNA, Ac-[~ HIPhe-tRNA 
and UACCA-[3 H] L.eu-AC were prepared as described 
[11,12]. 
3. Results 
3.1. Selective inhibitory effect of narciclasine in 
eukmyotic systems of polypeptide synthesis. 
Specific effect of the alkaloid in peptide bond 
formation 
Narciclasine strongly inhibits polypeptide syn- 
thesis in yeast polysomes as well as poly U-directed 
polyphenylalanine synthesis in a ribosomal system 
from rabbit reticulocytes but has no effect in a similar 
system from E. coli (fig.1). Polypeptide elongation is 
affected by narciclasine, since it inhibits peptide bond 
formation in three systems: a) the release of nascent 
peptides from yeast polysomes by [” Hlpuromycin, 
b) the reaction of the complex AC- [” H] Phe-tRNA- 
rabbit reticulocyte ribosome-poly U with puromycin 
and c) the fragment reaction assay with rabbit reticu- 
locyte ribosomes using UACCA- [3 H] Leu-AC as the 
donor substrate (tig.2). The most sensitive assay was 
the fragment reaction which was inhibited by 70% in 
the presence of lo-’ M narciclasine. 
3.2. Effect of narciclasine on substrate binding to 
the pep tidy1 transferase ten tre 
The inhibitory effect of narciclasine on the 
enzymic binding of [ l4 C] Phe-t RNA and the non- 
enzymic binding of AC- [3 H] Phe-tRNA to the ribosome 
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Fig. 1. Effects of narciclasine on [“Cl phenylalanine 
incorporation i yeast polysomes (- ), rabbit reticulocyte 
ribosomes (o-----o ) and E. coli ribosomes (- 1; [“Cl phenyl- 
alanine incorporation i  these systems in the controls was 
1.87,4.21 and 4.46 pmol respectively. The results are express- 
ed as the precentage ofcontrol incorporation of [I 4 Cjphenyl- 
alanine observed in the presence of narciclasine. Conditions 
as described in Materials and methods. 
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Fig.2. Effects of narciclasine on peptidyl- [ a H] puromycin 
formation by yeast polysomes ( -), AC-[ a H ] Phe-puro- 
mycin synthesis in the puromycin reaction assay by rabbit 
reticulocyte ribosomes (- ) and AC-[ 3 H] Leu-puromycin 
synthesis in the fragment reaction assay by rabbit reticu- 
locyte ribosomes (- ); 1.11, 0.198 and 0.022 pmol 
puromycin reacted in the controls in these assays respectively. 
The results are expressed as the percentage of the product 
formed in the presence on narciclasine compared to the 
control reaction in the absence of the alkaloid. Conditions as 
described in Materials and methods. 
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Fig.3. Effect of narciclasine on non-enzymic binding of Ac- 
[ 3 H] Phe-tRNA (-1, enzymic binding of [ ” C] Phe-t RNA 
(o----O) and sparsomycin-induced binding of UACCA-[ 3 H] 
Leu-AC (-4); 0.82, 6.98 and 0.088 pmol substrate were 
bound in the controls in these assays respectively. The results 
are presented as the percentage of the substrate bound in the 
presence of narciclasine compared to the controls in the 
absence of the alkaloid. 
is relatively weak compared to its blocking action of 
sparsomycin-induced binding of the donor substrate 
UACCA-[3 H] Leu-AC to rabbit reticulocyte ribosomes 
(tig.3). This result suggests that narciclasine blocks the 
fragment reaction assay by preventing the interaction 
of only the 3’ terminal end of the donor substrate to 
the peptidyl transferase centre of the 60s ribosome 
subunit; an action that might explain its reduced 
inhibitory effects on the binding of Ac-Rhe-tRNA to 
the ribosome. 
3.3. Effect of narciclasine on f 3 H]anisomycin and 
(I4 C] trichodermin binding to eukaryotic ribosomes 
The antibiotics anisomycin and trichodermin 
resemble narciclasine in that they also are specific 
inhibitors of peptide bond formation by eukaryotic 
ribosomes and affect substrate binding to the ribosome 
[ IO,1 21. We studied the binding of [” H] anisomycin 
and [‘4C]trichodermin [11,13,14] to yeast and 
rabbit reticulocyte ribosomes in the presence of 
narciclasine (table 1) and found that the alkaloid 
inhibited binding of [3 Hlanisomycin to both types 
of eukaryotic ribosomes. This observation supports 
the notion that the site of action of anisomycin and 
narciclasine at the ribosome level is identical or 
closely connected. On the other hand, narciclasine 
was a rather poor inhibitor of [14 C] trichodermin 
binding to ribosomes. This finding suggests different 
sites of action of trichodermin and narciclasine at the 
ribosome level in the peptidyl transferase centre. 
4. Discussion 
Our results indicate that narciclasine interacts with 
the 60s ribosome subunit. The alkaloid inhibits 
peptide bond formation by preventing the binding of 
the 3’ terminal end of the donor substrate to the 
peptidyl transferase centre. The inhibition by 
narciclasine of sparsomycin-induced binding of 
UACCA-[3 H] Leu-AC might be due to an indirect 
effect of the alkaloid, i.e. prevention of the associa- 
tion of the antibiotic with the ribosome. But it is 
most unlikely that narciclasine inhibits sparsomycin 
binding since the alkaloid strongly inhibits anisomycin 
association with its binding site on the 60s 
ribosome subunit, while sparsomycin does not inhibit 
Table 1 
Effect of narciclasine on the binding of [ 3 Hlanisomycin and [I* C] trichodermin 
to ribosomes 
Additions [’ Hlanisomycin binding (cpm) [ I4 C] trichodermin binding (cpm) 
Yeast Rabbit Yeast Rabbit 
ribosomes ribosomes ribosomes ribosomes 
Control 1186 1475 2005 1479 
+ lo-’ M narciclasine 79 117 1256 1045 
The binding assay was carried out as described in Materials and methods. 
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the binding of anisomycin [ 1 l] . Indeed all the 
evidence presented in this communication suggests 
that narciclasine acts on a moiety of the peptidyl 
transferase known as the ‘anisomycin area’ which is 
somehow independent from the sparsomycin site of 
action [ 15; review] . 
We conclude that the mode of action of narcic- 
lasine on mammalian ribosomes is similar to aniso- 
mycin and trichodermin. Narciclasine, like anisomycin 
and trichodermin, is active on the different eukaryotic 
cells and protein synthesizing systems which have 
been tested. Our binding experiments suggest hat the 
binding site of narciclasine and anisomycin might be 
the same. However the binding sites of narciclasine and 
trichodermin are not precisely the same although both 
inhibitors interact with the ‘anisomycin area’ of the 
peptidyl transferase centre. 
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